Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (30)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moens, A. L.
Right arrow Articles by Vrints, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moens, A. L.
Right arrow Articles by Vrints, C. J.
(Chest. 2005;127:2254-2263.)
© 2005 American College of Chest Physicians

Flow-Mediated Vasodilation*

A Diagnostic Instrument, or an Experimental Tool?

An L. Moens, MD; Inge Goovaerts; Marc J. Claeys, MD, PhD and Christiaan J. Vrints, MD, PhD

* From the Department of Cardiology, University of Antwerp, Antwerp, Belgium.

Correspondence to: An L. Moens, MD, University of Antwerp, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Antwerp, Belgium; e-mail: an.moens{at}uza.be

Brachial arterial flow-mediated dilation (FMD), assessed by high-resolution ultrasonography, reflects endothelium-dependent vasodilator function. FMD is diminished in patients with atherosclerosis and with coronary risk factors, and improves with risk-reduction therapy. Therefore, the measurement of FMD can be a good prognostic instrument in preventive cardiology, is useful to predict short-term postoperative cardiovascular events in a high-risk population and to assess long-term cardiovascular risk in a lower risk population, and is an excellent experimental tool to detect changes in endothelial function after new therapeutic interventions. In this review article, the pathophysiology of FMD, based on reactive hyperemia, is extensively discussed. Furthermore, an overview is given of the actual clinical indications of FMD measurement.

Key Words: coronary artery disease • endothelial dysfunction • flow-mediated vasodilation • review




This article has been cited by other articles:


Home page
 HeartHome page
A F Leite-Moreira and P Castro-Chaves
Heart failure: statins for all?
Heart, November 1, 2006; 92(11): 1537 - 1538.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.